Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Type/Product Area

Terms/Details (Date)


Ablynx NV*
(Belgium)

Kirin Brewery Co. Ltd. (Japan)

Collaboration focused on the use of Nanobodies as therapeutic products

Specifics on the research and license agreement were not disclosed (2/9)

Ablynx NV*
(Belgium)

Novartis AG (Switzerland)

Deal to to discover and develop Nanobody-based drugs against a number of targets in a range of diseases

Ablynx gets up-front fees, license fees and R&D funding and is eligible to receive milestone and royalty payments (1/18)

Ablynx NV*
(Belgium)

Centocor Inc. (unit of Johnson & Johnson)

Deal to jointly work on approaches for administration and delivery of Nanobody-based therapeutics

Centocor will fund the research; further terms were not disclosed (1/11)

ActiveSight
(unit of Rigaku
Americas Corp.)

Novo Nordisk A/S (Denmark)

ActiveSight will provide protein crystallography services for Novo

ActiveSight will co-crystallize Novo molecules with proteins expressed by ActiveSight; terms were not disclosed (1/23)

Affymax Inc.*

Takeda Pharmaceutical Co. Ltd. (Japan)

Takeda got rights to develop and sell Affymax's anemia product Hematide in Japan

Affymax gets a $17M up-front payment and a $10M equity investment; it also could get clinical and regulatory milestones of $75M, and double-digit royalties on sales (2/13)

Alkermes Inc.
(ALKS)

Eli Lilly and Co.

Deal to develop inhaled formulations of parathyroid hormone using Alkermes' AIR pulmonary delivery system

Alkermes gets up-front, development and potential milestone payments, as well as royalties on any sales; Lilly's PTH product Forteo was approved in 2002 (1/9)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Novartis AG (Switzerland)

They formed a collaboration to develop RNAi therapeutics for pandemic flu

The deal is in addition to a broad collaboration they signed in September 2005; terms were not disclosed (2/21)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Dharmacon Inc. (unit of Fisher Biosciences)

Dharmacon got nonexclusive rights to provide RNAi research products and services under Kreutzer-Limmer patents

The patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (1/5)

AlphaVax Inc.*

Wyeth

New deal gives Wyeth exclusive access to all relevant AlphaVax technologies for certain infectious diseases

The enhancement of their 1998 deal refocuses the disease targets and adds exclusivity; AlphaVax gets an equity investment and is entitled to significantly more funding than in the original deal (1/12)

Amira
Pharmaceuticals*

F. Hoffmann- La Roche Ltd. (Switzerland)

Amira will optimize compounds against inflammatory disease targets; separately, Amira got an option to license two clinical-stage Roche compounds

Under the research deal, Roche would have opt-in rights on two programs, for which it could pay Amira up to $287M, plus royal- ties; in the license deal, Amira has a one- year option to the Roche programs in certain indications; Roche could get significant Almira equity, $20M in milestones and royalties on sales (1/9)

Aphton Corp.
(PK:APHT)

BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan)

Apthon subsidiary Igeneon got nonexclusive rights to use BioWa's Potelligent technology

Igeneon will use the technology in development of a next-generation Lewis Y-specific antibody, IGN312; terms of the deal were not disclosed (2/14)

Argenta
Discovery Ltd.*
(UK)

Dr. Reddy's Laboratories (India)

Deal to jointly develop clinical candidates from a class of Dr. Reddy compounds for treating chronic obstructive pulmonary disease

They will fund development through Phase IIa trials, then continue development or license out candidates; terms of the deal were not disclosed (2/2)

Asterand plc
(LSE:ATD)

BTG plc (UK)

BTG got rights to a series of preclinical compounds for treating pain and related conditions

Asterand gets an undisclosed up-front payment and could earn milestone and royalty payments in the deal (1/30)

Astex
Therapeutics
Ltd.*
(UK)

Pfizer Inc.

Pfizer got nonexclusive rights to use Cytochrome P450 crystal structure data

Astex gets an up-front fee in the deal; further terms were not disclosed (1/24)

Athersys Inc.*

Bristol-Myers Squibb Co.

They extended deal under which Athersys is applying its RAGE technology to provide drug targets to BMS

Athersys is entitled to license fees for targets delivered to BMS, as well as potential milestone and royalty payments on resulting compounds (1/6)

AVEO
Pharmaceuticals
Inc.*

Mitsubishi Pharma Corp. (Japan)

AVEO acquired rights outside Asia to Mitsubishi's kinase inhibitor MP-412

AVEO intends to start clinical studies by mid-2006; the initial focus is solid tumors; terms of the deal were not disclosed (1/5)

Avigen Inc.
(AVGN)

SDI Diagnostics International Ltd. (unit of Sanochemia Pharmazeutika AG; Austria)

Avigen got North American rights to formulations of tolperisone (AV650), a small molecule for treating neuromuscular conditions

SDI gets $3M up front and is eligible to receive milestone and royalty payments; the product is approved in Europe; SDI also will manufacture the product (1/16)

Axonyx Inc.
(AXYX)

Daewoong Pharmaceutical Co. Ltd. (South Korea)

Daewoong got rights to sell the Alzheimer's drug candidate Phenserine in South Korean

Axonyx is entitled to royalty payments; Daewoong is responsible for development in South Korea; further terms were not disclosed (1/4)

BioCryst
Pharmaceuticals
Inc.
(BCRX)

Mundipharma International Holdings Ltd. (UK)

Mundipharma got rights to Fodosine in oncology fields, in Europe, Asia and Australia

BioCryst gets $10M up front and up to $155M in milestone payments, as well as royalties on sales; Mundipharma also will pay up to $25M in development costs (2/2)

BioSphings
AG*
(Germany)

Shogoo Pharmaceuticals KK (Japan)

Shogoo got worldwide rights to BioSphings' SPK-0601, a small molecule that acts on viral gene expression

BioSphings gets an up-front payment as well as potential milestone and royalty payments (2/2)

Biovitrum AB*
(Sweden)

Helsinn Healthcare SA (Switzerland)

Biovitrum got exclusive rights to the antiemetic drug Aloxi in the Nordic region

The product already is on the market in parts of Europe; terms of the deal were not disclosed (2/16)

Cadence
Pharmaceuticals
Inc.*

Bristol-Myers Squibb Co.

Cadence acquired rights in the U.S. and Canada to an intravenous formulation of acetaminophen

BMS gets an up-front payment and could receive milestone and royalty payments in the deal (2/22)

Caprion
Pharmaceuticals
Inc.*

Berlex Inc. (unit of Schering AG; Germany)

Collaboration using Caprion's CellCarta proteomics platform for biomarker discovery

Caprion will identify biomarkers in plasma resulting from administration of preclinical Berlex compounds; terms were not disclosed (1/24)

Cara
Therapeutics
Inc.*

ALZA Corp. (unit of Johnson & Johnson)

ALZA got rights to Cara's peripherally acting pain drug candidate CR665, which has completed a Phase Ia trial

Cara gets an up-front payment and could receive milestone payments and royalties on sales; it also retained a U.S. co-promotion option on intravenous products (1/5)

Celera
Genomics
(NYSE:CRA)

Applied Biosystems Group

Celera acquired ABG's 50% interest in their Celera Diagnostics joint venture

Both Celera and ABG are units of Applera Corp.; terms of the restructuring were not disclosed (1/9)

Cell Signaling
Technology
Inc.*

AstraZeneca plc (UK)

CST's PhosphoScan technology will be used on research on kinase-targeted compounds

The technology enables discovery of drug target phospho-profiles in cells and disease tissue; terms were not disclosed (1/10)

Cephalon Inc.
(CEPH)

Mylan Laboratories Inc.

Deal to use Mylan's transdermal technology to develop products for pain and central nervous system disorders

Mylan is entitled to milestone and royalty payments in the deal; further terms were not disclosed (1/11)

Cerimon
Pharmaceuticals
Inc.*

Novartis Pharma AG (Switzerland)

Cerimon acquired worldwide rights to Simulect (basiliximab) for treating inflammatory bowel disease

Novartis already markets the antibody for preventing organ rejection in renal transplant recipients; Cerimon is eligible for milestone payments in the deal, and Novartis would get a share of revenues on sales for IBD (2/21)

ChemGenex
Pharmaceuticals
Ltd.
(Australia;
CXSP)

Merck KGaA (Germany)

ChemGenex will provide preclinical support in the areas of diabetes, insulin resistance and complications

Payments under the three-year deal will depend on the amount and type of support provided; the deal followed target discovery work between the companies (1/16)

Chromos
Molecular
Systems Inc.
(Canada; TSE:CHR)

Pfizer Inc.

Expanded deal under which Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein

They also will collaborate to genetically engineer production cell lines; Pfizer will fund the new programs (1/9)

Ciphergen
Biosystems
Inc.
(CIPH)

Sanofi-Aventis Group(France)

Deal to discover biomarkers for a preclinical study in the field of oncology

Ciphergen will use its proteomics technologies in the effort; terms of the deal were not disclosed (2/7)

Codexis Inc.*

Bristol-Myers Squibb Co.

They extended deal focused on improving the biocatalyst productivity of a BMS product

Codexis gets additional research funding under the extension of the May 2005 deal; terms were not disclosed (1/31)

Cue Biotech
Inc.*

H. Lundbeck A/S (Denmark)

Deal to discover and develop drugs for central nervous system diseases and disorders

The focus is on small molecules targeting G protein- coupled receptors; terms of the deal were not disclosed (1/24)

CytoGenix
Inc.
(OTC BB:CYGX)

Fast Trak BioDefense (unit of GE Healthcare)

Collaboration to obtain biodefense-related federal contracts

Contract calls for them to compete for federal research projects; terms were not disclosed (12/27)

Diversa Corp.
(DVSA)

BASF (Germany)

Broad agreement to develop products for industrial applications

The deal expands a relationship between them from 2001 for developing biocatalysts; terms were not disclosed (2/16)

Emisphere
Technologies
Inc.
(EMIS)

Novartis AG (Switzerland)

A court said Emisphere's deal with Lilly on oral parathyroid hormone was properly terminated as of August 2004

The ruling allows Emisphere to now license its eligen technology for use with PTH to Novartis for treatment of osteoporosis; Emisphere is entitled to milestone and royalty payments (1/9)

Endocyte Inc.*

Bristol-Myers
Squibb Co.

BMS got rights to Endocyte's vitamin-targeting technology for targeting epothilone cancer chemotherapeutic agents

The deal follows an ongoing collaboration; Endocyte gets a $3M license payment and potential milestone and royalty payments (1/5)

EntreMed
Inc.
(ENMD)

Elan Corp. plc (Ireland)

EntreMed got rights to use Elan's NanoCrystal technology to develop the cancer product candidate Panzem NCD

Elan is eligible to receive milestone and royalty payments in the deal; also, Elan will manufacture Panzem NCD, a NanoCrystal technology formulation of the drug (1/10)

Epitome
Biosystems*

Bristol-Myers Squibb Co.

Epitome will develop biomarker assay panels for BMS

Epitome will use its EpiTag protein measurement platform in the deal; it is entitled to development funding and license fees (1/4)

EPIX
Pharmaceuticals
Inc.
(EPIX)

Schering AG (Germany)

Schering exercised its option to develop a gadofluorine derivative discovered in their collaboration

The product is intended for the diagnosis of atherosclerosis and other vascular diseases; EPIX would get royalties on any resulting sales (2/10)

Evotec AG
(Germany; FSE:EVT)

Cellomics Inc. (unit of Fisher Biosciences)

Evotec Technologies GmbH got rights to Cellomics' High Content Screening technology

The companies also are collaborating to develop and market combined offerings in cell biology solutions; terms were not disclosed (1/30)

Evotec AG
(Germany;
GmbH (Germany)

Boehringer Ingelheim started in September 2004

They expanded and extended drug discovery collaboration research support, along with potential

The focus was extended from GPCR targets to other classes; Evotec gets ongoing FSE:EVT) milestone and royalty payments (1/17)

Evotec AG
(Germany;
FSE:EVT)

F. Hoffmann- La Roche Ltd. (Switzerland)

Evotec got rights to two monoamine oxidase-B inhibitors that are in Phase I trials for Alzheimer's disease

Roche gets an up-front fee and potential milestone and royalty payments; it also retained a late-stage co- development option; Roche would get Evotec stock upon initiation of Phase II trials (1/9)

Galapagos NV
(Belgium;
Euronext:GLPG)

BASF (Germany)

They extended three research collaborations into 2006; Galapagos division BioFocus is providing the services

BASF will pay compound supply and access fees in the contract extensions, which are valued at more than €700,000 (2/2)

Galapagos NV
(Belgium;
Euronext:GLPG)

Boehringer Ingelheim GmbH (Germany)

Three-year deal in field of autoimmune discovery research; Galapagos division BioFocus will do the work

Galapagos gets up-front fees, R&D funding and could receive milestone fees, which together could exceed €2M (1/16)

GeneGo Inc.*

Merck & Co. Inc.

Merck extended for two years its right to use GeneGo technologies

Merck is using the MetaCore and MetaBase technologies in R&D programs; terms of the deal were not disclosed (1/9)

G2 Therapies
Ltd.*
(Australia)

Novo Nordisk A/S (Denmark)

Deal to develop and market anti-inflammatory drugs based on G2's C5a receptor antibodies

G2 gets $6M up front and up to $96M in milestone payments, as well as royalties on resulting sales; it also gets expense reimbursement (2/8)

Hybrigenics
SA*
(France)

Theramex (affiliate of Merck KGaA; Germany)

Hybrigenics got worldwide rights to inecalcitol, a synthetic vitamin D analogue

Hybrigenics intends to develop products for cancer and partner the drug in other indications; terms of the deal were not disclosed (2/7)

IDM Pharma
Inc.
(IDMI)

Genesis Pharma (Greece)

Genesis got rights in southeast Europe to the immune system stimulator Junovan

The product has completed a Phase III trial in osteosarcoma; IDM is entitled to an upfront license fee and sales-based milestone payments (2/21)

ImQuest
Pharmaceuticals
Inc.*

Samjin Pharmaceutical Co. Ltd. (South Korea)

Deal under which ImQuest will provide preclinical and clinical development support

ImQuest will work on small molecules provided by Samjin; terms of the deal were not disclosed (1/24)

Innovive
Pharmaceuticals
Inc.*

Nippon Shinyaku Co. Ltd. (Japan)

Innovive got all rights outside Japan to NS-187, an inhibitor of Bcr-Abl and Lyn kinase

Innovive will develop the product for chronic myelogenous leukemia; Phase I trials are expected in 2006; terms of the deal were not disclosed (1/5)

Inspire
Pharmaceuticals
Inc.
(ISPH)

Boehringer Ingelheim International GmbH (Germany)

Inspire acquired rights to develop and market an intra- nasal form of epinastine in the U.S. and Canada for treating or preventing rhinitis

BI gets an up-front license fee and would get single-digit royalties on resulting sales; it also retained rights outside the U.S. and Canada; Inspire will fund development (2/21)

KAI
Pharmaceuticals
Inc.*

Sankyo Co. Ltd. (subsidiary of Daiichi Sankyo Co. Ltd; Japan)

Collaboration to develop drugs for cardiovascular disease; the initial focus is on the Phase I/II delta protein kinase C inhibitor KAI-9803

KAI gets $20M up front and could get mile- stones of up to $300M for two indications for KAI-9803, as well as milestone payments for future delta PKC inhibitors; Sankyo gets global rights, will fund all development and would pay double-digit royalties on sales (1/9)

Kalypsys Inc.*

Alcon Inc.

Kalypsys will use its technologies for the discovery of ophthalmic drug candidates under a four-year deal

Kalypsys gets an access fee, research support and potential milestone payments, as well as royalties on any sales; Alcon also got preferred partnering access to compounds from Kalypsys programs (1/4)

Keryx Bio-
pharmaceuticals
Inc.
(KERX)

Panion & BF Biotech Inc. (Taiwan)

Keryx gained rights outside Asia to Zerenex, an oral iron-based compound

Panion is entitled to up-front, milestone and royalty payments on the drug, which is in Phase II clinical development for treating hyperphosphatemia (2/15)

LibraGen*
(France)

Pierre Fabre Medicament (France)

LibraGen will optimize the synthesis of a Pierre Fabre molecule

LibraGen will use its enzymatic technologies in the deal, terms of which were not disclosed (1/5)

Locus
Pharmaceuticals
Inc.*

Eli Lilly and Co.

Locus will use its computational technologies to design small- olecule compounds for Lilly

The focus is a protein kinase target identified by Lilly; terms of the deal were not disclosed (1/31)

Medarex
Inc.
(MEDX)

Organon NV (the Netherlands)

Organon got rights to use Medarex's UltiMAb technology for antibody discovery and development

Medarex is entitled to license fees, milestone payments and royalties on any resulting sales (2/1)

MerLion
Pharmaceuticals
Pte. Ltd.*
(Singapore)

Novartis Institute for Tropical Diseases (Singapore)

Collaboration initially focused on discovering compounds for treating Dengue fever

MerLion will screen its natural compounds against an NITD target; Novartis has an option to license resulting candidates, and also can license compounds for different indications (1/19)

Micromet AG*
(Germany)

Undisclosed pharmaceutical company

The unnamed company got rights to develop and sell a single-chain antibody product for treating cancer

The deal was made under Micromet's marketing deal with Enzon Pharmaceuticals Inc., which will get a share of any proceeds (1/18)

Micromet AG*
(Germany)

Abbott Laboratories

Abbott gained a research license to single-chain antibody technology

The deal was made under Micromet's marketing deal with Enzon Pharmaceuticals Inc., which will get a share of any proceeds (1/18)

Monogram
Biosciences
Inc.
(MGRM)

Merck & Co. Inc.

Monogram will apply its testing technologies for use in Phase III trials of MK-0518, Merck's HIV-1 integrase inhibitor

The PhenoSense and GeneSeq technologies will be used for HIV phenotypic and genotypic testing; terms of the deal were not disclosed (2/21)

Nastech
Pharmaceutical
Co. Inc.
(NSTK)

Procter & Gamble Pharmaceuticals Inc.

P&G got worldwide rights to Nastech's PTH1-34, a para- thyroid hormone nasal spray for treating osteoporosis

Nastech gets $10M up front and milestone payments up to $22M in the first year; total payments could reach $577M if all goals are reached; Nastech also would get double-digit royalties on sales (2/1)

Novosom
AG*
(Germany)

Boehringer Ingelheim Pharma GmbH (Germany)

Collaboration to validate liver and pulmonary targets in vivo using siRNA technology from Novosom

BI will fund the program; further terms were not disclosed (1/16)

NPS
Pharmaceuticals
Inc.
(NPSP)

AstraZeneca plc (UK)

They extended for at least three years a deal to discover and develop drugs targeting metabotropic glutamate receptors

AstraZeneca already is in Phase I trials with a collaboration candidate; the focus is on treating central nervous system and gastrointestinal disorders; terms were not disclosed (2/8)

Nuvelo Inc.
(NUVO)

Bayer HealthCare AG (Germany)

Bayer got rights outside the U.S. to Nuvelo's Phase III thrombolytic drug alfimeprase; Nuvelo retained all U.S. rights

Nuvelo gets $50M up front, up to $165M in development milestones and up to $170M in sales milestones, as well as royalties up to 37.5%; Bayer also will pay 40% of development costs (1/5)

Ocera
Therapeutics
Inc.*

Kureha Corp. (Japan)

Ocera got rights to AST-120 in Europe and North America

Ocera is planning to start trials of the product, which is targeted at liver and gastro- intestinal diseases; the initial indication is Crohn's disease (1/17)

Opsona
Therapeutics
Ltd*
(Ireland)

Wyeth Pharmaceuticals

Deal to discover and market compounds to treat inflammatory diseases, based on Toll-like receptor targets

Opsona gets an up-front payment and R&D funding, as well as potential milestone and royalty payments; it also has an option to develop resulting drugs in topical indications (2/13)

Oscient
Pharmaceuticals
Corp.
(OSCI)

Pfizer SA de CV (Mexico)

Pfizer got rights to the antibiotic product Factive in Mexico

Oscient gets an up-front payment, as well as potential regulatory and sales milestones and royalties on sales (2/7)

PerlegenSciences Inc.*

Pfizer Inc.

Four-year deal for whole- genome and replication studies to identify genes associated with diseases and to predict patient responses to certain drugs

Perlegen gets research payments; the companies will share in certain resulting intellectual property rights; the deal followed by one day a $50M equity investment in Perlegen by Pfizer; they have been partners since 2002 (12/28)

Primagen
Holding BV*
(the Netherlands)

BioMerieux SA (France)

BioMerieux got rights to a newly discovered coronavirus implicated in respiratory diseases

BioMerieux plans to develop a test for the virus, CoV-NL63; it also has sublicensing rights; terms were not disclosed (2/1)

Progenics
Pharmaceuticals
Inc.
(PGNX)

Wyeth

Deal to develop and market Progenics' Phase III product methylnaltrexone (MNTX) for treating opioid-induced side effects

Progenics gets $60M up front and up to $356.5M in milestone payments, as well as royalties on any sales; Progenics also retained a U.S. co-promotion option(12/23)

PDL BioPharma
Inc.
(PDLI)

Merck & Co. Inc.

Merck got nonexclusive rights under PDL's humanization patents to develop antibodies against two antigens

PDL is entitled to an up-front licensing payment, development milestones and royalties on any sales; the antigens were not disclosed (12/3)

Replidyne Inc.*

Forest Laboratories Inc.

Deal for the commercialization of Replidyne's oral antibiotic faropenem medoxomil in the U.S.; an NDA was filed in January

Replidyne gets $50M up front and potential milestone payments; it also would get royalties on sales; Replidyne retained certain marketing rights (2/13)

Sangamo
BioSciences
Inc.
(SGMO)

Pfizer Inc.

New deal expands the scope of existing collaboration in the field of enhanced protein production

Pfizer will fund further research at Sangamo, which will use its zinc finger DNA-binding protein technology to develop additional cell lines (1/4)

Sareum
Holdings plc
(UK; AIM:SAR)

UCB Pharma (Belgium)

Sareum will provide protein structure determination capabilities to accelerate UCB research in cancer

Sareum is entitled to access fees and milestone payments in the deal; further terms were not disclosed (1/26)

Sareum
Holdings plc
(UK; AIM:SAR)

H. Lundbeck A/S (Denmark)

Sareum will provide protein structure determination capabilities to accelerate discovery research at Lundbeck

Sareum is entitled to research fees and milestone payments in the deal; specific terms were not disclosed (1/19)

Sareum
Holdings plc
(UK; AIM:SAR)

Organon NV (the Netherlands)

Sareum will generate lead chemical series against two Organon autoimmune disease protein targets

Sareum is entitled to research fees and milestone payments in the deal; specific terms were not disclosed (1/17)

Scottish
Biomedical
Ltd.*
(UK)

Chong Kun Dang (South Korea)

Collaboration on development of a drug for diabetes

Scottish Biomedical will provide chemistry and biology services on small molecules believed to be active against a diabetes target; terms were not disclosed (1/31)

Senexis Ltd.*
(UK)

BTG plc (UK)

Senexis got rights to inhibitors of amyloid-induced toxicity and neuroinflammation

BTG is entitled to milestone and royalty payments in the deal (2/2)

Shanghai
Genomics Inc.
(China; affiliate
of GNI Ltd.)

Organon NV
(the Netherlands)

Collaboration to advance Organon's program for identifying more-selective steroid hormone receptor modulators

The deal, initially for two years, will focus on the areas of rheumatoid arthritis, atherosclerosis and oncology; terms were not disclosed (1/24)

Targacept
Inc.*

AstraZeneca plc (UK)

Deal to develop and market Targacept's Phase II drug TC- 734 for Alzheimer's disease and other cognitive disorders

Targacept gets $10M up front, $26M in research funding and would get $20M if AstraZeneca starts a Phase II program; Targacept also could earn about $244M in milestone payments and double-digit royalties on sales (12/28)

Tripos Inc.
(TRPS)

Wyeth Pharmaceuticals

Wyeth will use Tripos' discovery informatics technology as the basis for its information technology solution

Tripos expects to receive about $5M in software license and service fees over 12 to 18 months, with certain payments contingent on milestone achievements (1/11)

Trubion
Pharmaceuticals
Inc.*

Wyeth Pharmaceuticals

Deal to develop and sell drugs for inflammatory diseases and cancer based on Trubion's Small Modular Immuno-pharmaceutical technology

Trubion gets $40M up front and up to $760M in milestone payments, as well as royalties on sales; Trubion retains an option to co-promote CD20- targeted therapies in the U.S. for certain indications; Wyeth also would invest in Trubion if it conducts an initial public offering (1/3)

Vaccinex Inc.*

Schering AG (Germany)

Deal to identify disease targets and potentially develop drugs for treating certain cancers

Vaccinex gets a technology access fee and research funding and is eligible for milestone and royalty payments; its also has certain co-development options (2/10)

VaxGen Inc.
(PK:VXGN)

Becton, Dickinson and Co.

Deal to evaluate BD's Micro Injection technology to deliver VaxGen's recombinant anthrax vaccine candidate

The collaboration will include a Phase I trial of the dermal injection; the work is being funded through a contract between BD and the Department of Defense (2/21)

Xencor Inc.*

Centocor Inc. (unit of Johnson & Johnson)

Centocor got nonexclusive rights to use ImmunoFilter technology to evaluate the immunogenicity of its proteins

Xencor gets annual license fees under the multiyear deal; further terms were not disclosed (2/14)

Xencor Inc.*

Eli Lilly and Co.

Lilly got nonexclusive rights to use Xencor's ImmunoFilter technology to evaluate the immunogenicity of its proteins

Terms of the multiyear licensing deal were not disclosed (1/18)

Xencor Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

They extended deal to create monoclonal antibodies with differentiated pharmacological profiles

Roche is applying Xencor's XmAb Fc domains to enhance the efficacy of an antibody against a cancer target; Xencor gets additional fees under the extension and remains entitled to milestone and royalty payments (1/4)

YM BioSciences
Inc.
(Canada;
TSE:YM)

Sanofi-Aventis Group (France)

Deal to investigate the combination of tesmilifene and docetaxel for treating metastatic breast cancer

The initial trial will enroll up to 39 patients; prior Phase III data on the combination showed increased survival; terms were not disclosed (1/10)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange.

No Comments